STUDresearch · Non-peptide
Aleniglipron
Also known as
GSBR-1290 · Structure Therapeutics oral GLP-1 · aleniglipron pill
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
Oral tablet
Metabolic / GLP-1 class
Systemic once-daily oral small-molecule GLP-1 agonist.
What people say
An investigational daily oral GLP-1 that people compare with injections and orforglipron for convenience, weight loss and GI tolerability. Phase 3 is underway; this is not an approved consumer pill.
Doses people talk about
ACCESS, ACCESS II and earlier PK cohorts used different dose roles. Trial target amounts are not interchangeable with orforglipron or oral semaglutide milligrams.
How it may feel
The checked thread is pipeline discussion, not an aleniglipron use diary. Week-one nausea and appetite changes in the original notes are class comparisons, not an established aleniglipron timeline.
ACCESS II targets120 / 180 / 240 mg once daily
Maintenance targets after trial titration. The 44-week 16.3%/16.0% headlines are placebo-adjusted results at 180/240 mg, not immediate effects.
Earlier study contexts45 / 90 / 120 mg once-daily ACCESS targets
The separately discussed 20 mg was an earlier capsule-to-tablet PK titration step, not an ACCESS maintenance arm.
Lower-start study cohorts2.5 mg daily for the first ~4 weeks
A study-design comparison with earlier 5 mg starts, not an instruction to start or increase a dose. Separate cohorts cannot isolate the reason for improved tolerability.
Half-life & effect duration
- Half-life in the body
- 120 mg tablet · study formulationAbout 8.5 hours
- 60 mg tablet · study formulationAbout 4.7 hours
- 60 mg capsule · study formulationAbout 6.5 hours
- 120 mg capsule · study formulationAbout 5.3 hours; sampling may underestimate it
- Felt duration people report
- Felt durationNo consistent firsthand window reported
- During trialsDigestive effects occurred during treatment
Cycles people discuss
The program studies repeated daily treatment for chronic weight management, not a bodybuilding on/off cycle. First patients entered Phase 3 by August 2026; outcomes and approval remain unresolved.
Timing
Once daily is the studied regimen. Company discussion describes fewer Rybelsus-style fasting rules, but no future consumer label or all-day appetite effect can be assumed.
Stacks
ACCESS studied aleniglipron without another weight-loss drug as the study treatment. Orforglipron, Rybelsus, semaglutide and tirzepatide are comparisons here—not a recommended combination.
Watch for
Vomiting / nausea: Important adverse effects in ACCESS. Later 2.5 mg starting cohorts looked more tolerable than earlier 5 mg cohorts at interim follow-up, but this was not a randomized start-dose comparison or a guarantee for an individual.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
About 8.5 hours was reported for the studied 120 mg tablet formulation.
The sponsor reports different values for 60 mg tablets and capsules. This is a formulation-specific plasma measurement, not appetite suppression lasting 8.5 hours.
Sponsor-reported study data; not a universal future product value. The separate 120 mg capsule result had limited late sampling; daily dosing is the studied regimen, not inferred solely from this number.
- GSBR-1290 capsule-to-tablet human PK results (opens in a new tab)Sponsor June 2024 presentation, slides 11 and 19, actual HTML table: overweight/obese adults; 120 mg tablet C1/C2 geometric-mean elimination t½ 8.5 h, 60 mg tablet 4.7 h, 60 mg capsule 6.5 h; separate 120 mg capsule 5.3 h.Sponsor-reported plasma PK, not peer-reviewed individual data or felt duration. The 120 mg capsule estimate lacked samples beyond 24 h and may be underestimated. Figures are formulation/dose-specific, not a universal future commercial tablet estimate; NHP insulin thresholds are separate.
Felt duration people report
A dependable firsthand felt window is not established in the checked discussion.
The forum debates convenience and trial results. ACCESS recorded GI effects during treatment, but neither its 36-week outcomes nor other GLP-1 users' stories establish a personal onset/offset clock.
No verified aleniglipron diary or clean washout in this bounded source set; missing experience is not proof of no subjective effects.
- Oral GLP-1 pipeline discussion and critical replies (opens in a new tab)Actual May 29, 2026 OP and visible replies by smartaxe21, NilliaLane and LeoKitCat: needle avoidance, oral convenience, tolerability debate and trial-method questions.Pipeline discussion, not a firsthand aleniglipron use diary. OP confuses the name with aleglitazar; a reply mixes ACCESS II and OLE endpoints. Neither error, speculative liver claims nor the supposed plateau is adopted. No onset, duration or washout can be extracted.
- ACCESS — original phase 2b trial (opens in a new tab)Actual article abstract, Trial design, Tolerability/Discussion and Methods; Table 2 separately accessed at /tables/2. 230 randomized; 45/90/120 mg daily targets after four-week steps; week-36 endpoints and prospectively collected GI events.ACCESS, not ACCESS II. Table 2 covers baseline to week 36, not one dose's acute reaction rate. OLE 2.5 mg starters were a separate cohort, not a randomized 2.5-versus-5 mg tolerability comparison. Article text fetched directly where browser-readable retrieval failed.
Other context in this card
- ACCESS II 44-week results and lower-start cohorts (opens in a new tab)March 16, 2026 release: ACCESS II results table/primary efficacy estimand footnote; 85 enrolled; 120/180/240 mg targets; 28–44-week re-randomized subgroup; Body Composition and OLE paragraphs; safety paragraph.Sponsor topline/interim results. Placebo-adjusted percentages differ from baseline changes; 3.7% discontinuation is one of 27 who reached ≥120 mg, not all enrollees. Separate cohorts cannot prove that 2.5 mg alone caused better tolerance; cross-drug comparisons are not head-to-head.
- ACCESS and ACCESS II — distinct study timelines (opens in a new tab)Actual March 16, 2026 presentation, slides 4, 7–9 and 11–12: prior week-36 ACCESS versus ACCESS II results, randomized sample and later-dose subgroup denominators.Sponsor presentation; not a head-to-head study or personal regimen. The deck has 73 randomized whereas the same-day release says 85 enrolled; no equivalence is assumed. The later 1/27 discontinuation count is not the full cohort.
- Aleniglipron ACCOMPLISH Phase 3 initiation (opens in a new tab)August 6, 2026 release, opening and aleniglipron business-update paragraph: first patients dosed in ACCOMPLISH-1 and -2. Actual publisher HTML accessed directly after web-reader 403.Sponsor status report as of August 6, accessed September 6, 2026. Phase 3 initiation is not approval or evidence of long-term success.
What people say
- ACCESS II 44 wk: Placebo-adjusted mean ~16.3% at 180 mg and ~16.0% at 240 mg (~37–39 lb in the press math). trial
- ACCESS II 36-week context: Earlier toplines cited up to ~15.3% placebo-adjusted mean weight loss at 180 or 240 mg—mid-teens, not 'high teens.' The separate ACCESS study tested 45, 90 and 120 mg, reaching 11.3% placebo-adjusted at 120 mg. trial
- Oral convenience: Daily tablet, no pin, no Rybelsus water ritual in the company’s telling. trial
- 2.5 mg starting-cohort comparison: Later cohorts began at 2.5 mg rather than the earlier 5 mg and reported fewer AE-related discontinuations at interim follow-up. This is the titration comparison people repeat, not a randomized demonstration that 2.5 mg alone caused the difference or a personal start-dose instruction. trial
Doses people talk about
- No consumer label. forum
- ACCESS II maintenance talk: 120 / 180 / 240 mg once daily after titration. trial
- Earlier dose contexts: ACCESS used 45/90/120 mg once-daily target arms. The separately discussed 20 mg number occurred as a titration step in an earlier capsule-to-tablet PK cohort, not an ACCESS maintenance arm. These are distinct from the ACCESS II 180/240 mg efficacy headlines. trial
- Lower starting-dose study context: Later cohorts used 2.5 mg daily for the first ~4 weeks before further study titration; Phase 3 planning also used that initial-dose concept. This describes trial design, not a consumer starting dose or a step-up schedule. trial
- Once daily. Not weekly. trial
How it may feel
- Class oral-GLP feel: Week-1 nausea, quieter appetite and difficulty meeting protein intake are borrowed from orforglipron/semaglutide discussions, not an established aleniglipron diary timeline. The actual thread checked here discusses the pipeline, not firsthand aleniglipron use. forum
- After a stable dose: The community's “it gets quieter” GLP comparison is consistent with later attenuation of GI events in ACCESS, but not everyone tolerates treatment and some discontinued. It is not a promise that continuing through symptoms resolves them. forumtrial
- If food cannot be kept down: The later 2.5 mg versus earlier 5 mg starting-dose comparison is trial-design context, not an instruction to change doses or persist through vomiting. Inability to keep food or fluids down needs medical assessment. forum
- Titration: GI events in ACCESS were concentrated earlier in treatment and generally attenuated later, not a proven peak at every step. The rough 30–40% vomiting / ~5% placebo shorthand refers to cumulative events over baseline–week 36: 40.0%, 44.6% and 31.7% in the 45/90/120 mg target arms versus 5.4% placebo. trial
Cycles people discuss
- Daily study treatment: Repeated once-daily oral use is studied for chronic weight management; it is not a weeks-on/off bodybuilding cycle or a statement that every GLP-1 drug is dosed daily. trial
- Phase 3 timeline: The earlier 2H 2026 target is now underway: the company reported first dosing in ACCOMPLISH-1 and -2 on August 6, 2026. Results and approval remain unresolved. trial
Timing
- Food rules: Company’s pitch is fewer Rybelsus-style empty-stomach rules. Confirm against a future label. forum
- Formulation-specific human PK: A June 2024 sponsor table reports a geometric-mean plasma elimination half-life of 8.5 hours for 120 mg tablets in overweight/obese adults. It separately reports 4.7 hours for 60 mg tablets and 6.5 hours for 60 mg capsules; the 120 mg capsule estimate was 5.3 hours, potentially underestimated because sampling stopped at 24 hours. These are not felt durations. trial
- Why daily is the regimen discussed: The clinical program studies once-daily oral administration, unlike weekly injectable semaglutide schedules. Being a small molecule does not by itself establish a dosing interval, and a plasma half-life is not a full-day appetite guarantee. trial
More on what it is
- Why people talk about it: Stock/obesity Twitter after ACCESS focuses on roughly 16% placebo-adjusted weight loss at 44 weeks with 180 mg in ACCESS II. Vomiting and the later 2.5 mg starting-dose cohorts are the other recurring topic; separate cohorts do not prove that this starting dose alone fixed tolerability. forum
- Vs orforglipron: Same class fight. Forums/investors pick on vomit rates vs Lilly’s pill. Actual pipeline-thread replies debate needle avoidance, titration and study comparability rather than describing personal use; these are not head-to-head tolerability results. forum
- Not a gray “oral GLP powder.” forum
- What it is: Structure Therapeutics’ daily oral non-peptide GLP-1 (GSBR-1290). Not Rybelsus (oral semaglutide with its own absorption rules). Still investigational, not approved; the former 2H 2026 Phase 3 target progressed to first patients dosed in ACCOMPLISH-1 and -2 by August 6, 2026. trial
- How it works: Small-molecule GLP-1 receptor agonist — satiety, slower gastric emptying and glucose effects are the class rationale; this investigational program uses oral tablets. trial
- Evidence: Phase 2b ACCESS in *Nature Medicine*; ACCESS II 44-week topline; body-composition / OLE extras. trial
Stacks
- Mental compare: orforglipron, Rybelsus, injectable sema/tirz. forum
- Solo in ACCESS. trial
Storage notes
- A pill: Room-temperature pharmacy storage is part of the convenience discussion, not a verified instruction for every investigational tablet or future product. Actual packaging requirements remain formulation-specific. forum
Watch for
- Not orforglipron mg-for-mg. forum
- Unapproved. forum
- Vomiting / nausea: Important adverse effects in ACCESS. Later 2.5 mg starting cohorts looked more tolerable than earlier 5 mg cohorts at interim follow-up, but this was not a randomized start-dose comparison or a guarantee for an individual. trial
- AE dropout ~10%: The 10.4% overall figure belongs to ACCESS, not ACCESS II. The separately quoted ACCESS II 3.7% is 1 of 27 re-randomized participants during weeks 28–44, not the whole study population. trial
- Liver/QTc: The company reported no DILI or QTc-prolongation events in the programs summarized on March 16, 2026. That is a dated observation, not proof of no future risk; aleniglipron remains investigational. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.